Please try another search
Novartis Gene Therapies, Inc., a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. It offers AVXS-101, an AveXis’ gene therapy, for the treatment of spinal muscular atrophy (SMA) type 1, which is in phase 1 clinical trials. The company was formerly known as AveXis, Inc., and changed its name to Novartis Gene Therapies, Inc. in September 2020. The company was incorporated in 2010 and is based in Bannockburn, Illinois. Novartis Gene Therapies, Inc. operates as a subsidiary of Novartis AG.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review